Tilomisole

Tilomisole (Wy 18251) is a benzimidazothiazole experimental agent with anti-inflammatory activity. Tilomisole causes less agranulocytosis than levamisole, but retains immunomodulating capabilities. Tilomisole is orally active. Tilomisole has the potential for the research of cancer and inflammation[1][2].

Product Specifications

CAS Number

[58433-11-7]

Product Name Alternative

Wy 18251

UNSPSC

12352005

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tilomisole.html

Solubility

10 mM in DMSO

Smiles

O=C(CC1=C(C2=CC=C(Cl)C=C2)N3C4=C(C=CC=C4)N=C3S1)O

Molecular Formula

C17H11ClN2O2S

Molecular Weight

342.80

References & Citations

[1]Dillman RO, et al. WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients. Mol Biother. 1992;4 (1) :10-14.|[2]Darwish SA, et al. New tilomisole-based benzimidazothiazole derivatives as anti-inflammatory agents: Synthesis, in vivo, in vitro evaluation, and in silico studies [published online ahead of print, 2022 Jan 29]. Bioorg Chem. 2022;120:105644.